A new study published in the journal JAMA Pediatrics evaluated the use of exenatide as a treatment for adolescent obesity.  Exenatide, a GLP-1 receptor agonist, is a twice daily injection that suppresses appetite and increases the feeling of fullness.  The study enrolled adolescents between the ages of 12 and 19 with BMI ≥35. After three months, patients assigned to exenatide cut their BMI by 2.7% compared with 0.2% in the placebo group. No patients developed hypoglycemia or pancreatitis.  What treatment options do you suggest to your obese teenage patients looking to lose weight?

For more information, please see the abstract in JAMA Pediatrics.